Clinical Trial Search

Primary: Percentage of Non-cirrhotic Treatment-Naïve Participants Who Are Eligible for Interferon (IFN)-Based Therapy and Who Have High Viral Load in the DB Active Treatment…

Primary: Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score. — -3.32; -4.35; -5.58; -3.48 Units on a scale — p=0.0093

Primary: FEV1 AUC0-3h Response — -0.014; 0.205; 0.285; 0.316 L — p=<0.0001

Primary: Percentage of Participants With Intraoperative Hemostasis at Target Bleeding Site Within 3 Minutes — 80.7; 50.0; 87.5; 44.4 percentage of participants — p=<0.001

Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24 — -0.67; -0.06 %A1C — p=<0.001

Primary: Heart Rate (HR) — 120; 121; 107; 121 bpm — p=<0.01

Primary: Change From Baseline in A1C at Week 24 — -0.47; -0.43 Percent

Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.35; -1.22 percentage of glycosylated haemoglobin

Primary: Time to Cessation of Otorrhea — 6.83; 22; 4.94 days

Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) — -1.85; -1.73 Percent (%) glycosylated haemoglobin

Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.33; -1.09 percentage of glycosylated haemoglobin

Primary: Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52 — 1.58; 0.36 units on a scale — p=<0.001

Primary: Change From Baseline to Week 8 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score — -23.07; -24.79; -22.61 Score on a Scale — p=0.226

Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.28; -1.30 percentage of glycosylated haemoglobin

Primary: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment — -0.73; -0.68 percentage of glycosylated haemoglobin